Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
MYGNMyriad(MYGN) ZACKS·2024-07-16 03:06

Myriad Genetics, Inc. (MYGN) recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).The latest collaboration should help Myriad Genetics strengthen its market presence and broaden patients’ access to the benefits of MRD testing.About MRD TestMRD tests are blood-based diagnostic tools that enable clinicians to monitor therapeutic responses to cancer treatment more closely than with traditional cancer de ...